Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Chief Commercial Officer | January 22, 2024 | January 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SELLAS Life Sciences Group, Inc.
Report date January 22, 2024 · Filed January 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,918 |
Reported balance
After 2024-01-22 transaction · row 1
1 source rowRow 1 · 2024-01-22 · Grant · Acquired 20,000 · Balance 40,918 F1: The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2034-01-22 | Direct | 30,000 |
Reported balance
After 2024-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-22 · Grant · Acquired 30,000 · Balance 30,000 F2: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
F2: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Other · Disposed 200,891 · Balance 0 F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.79 · Expires 2026-09-19 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
F2: All options were vested and exercisable as of the effective time of the merger.
F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2024 Filed Jan 25, 2024 11:02 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001104659-24-006396 · tm243935-2_4seq1.xml · derivative · entry 2 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-01-22 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 11:02 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-006396 · tm243935-2_4seq1.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,918 F1 · shares: The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 21:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherClass A Common Stock | 1,082 | $1.08 | $1,168.56 |
DisclosureSEC source: 0001104659-23-124687 · tm2332459-2_4seq1.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,918 F1 · kind: Transaction relates to shares of common stock withheld by SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · shares: Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:14 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-23-010637 · tm235353d6_4seq1.xml · derivative · entry 2 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-02-02 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:14 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010637 · tm235353d6_4seq1.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · shares: The Reporting Person received an award of 12,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 20:05 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001104659-22-033927 · tm229354-1_4seq1.xml · derivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-14 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $9.79 | Not disclosed |
DisclosureSEC source: 0001104659-20-071832 · a4.xml · derivative · entry 2 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-09-19 F3 · price: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of the effective time of the merger. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | OtherCommon Stock | 200,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-071832 · a4.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 272 | $11.51 | $3,130.72 |
DisclosureSEC source: 0001104659-20-057631 · a4.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,658 F1 · shares: In connection with the vesting of 1,878 shares on May 2, 2020 a total of 272 shares were sold by the Company on May 4, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on May 4, 2020 was $11.81 to $12.02. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · balance_after: Of the shares listed, 144,425 shares are restricted stock. Read SEC document |
| March 09, 2020 Filed Mar 13, 2020 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 1,266 | $5.00 | $6,330.00 |
DisclosureSEC source: 0001104659-20-033490 · a4.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,930 F1 · shares: In connection with the vesting of 3,253 shares on March 8, 2020 a total of 1,266 shares were sold by the Company on March 9, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on March 9, 2020 was $5.00 to $5.02. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · balance_after: Of the shares listed, 146,303 shares are restricted stock. Read SEC document |
| February 10, 2020 Filed Feb 14, 2020 21:29 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 105,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-022139 · a4.xml · nonDerivative · entry 2 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,196 F4 · shares: The 105,939 restricted shares will vest in three installments as follows: 35,313 shares on February 24, 2021; 35,313 shares on April 6, 2022; and 35,313 shares on January 25, 2023. F5 · balance_after: Of the shares listed, 149,556 shares are restricted stock. Read SEC document |
| February 07, 2020 Filed Feb 14, 2020 21:29 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 5,064 | $6.72 | $34,030.08 |
DisclosureSEC source: 0001104659-20-022139 · a4.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,257 F1 · shares: In connection with the vesting of 12,388 shares on February 6, 2020 a total of 5,064 shares were sold by the Company on February 7, 2020 in order to satisfy the reporting person's tax witholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold was $6.66 to $6.81. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the shares listed, 43,617 shares are restricted stock. Read SEC document |
| December 27, 2019 Filed Jan 3, 2020 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 116 | $10.48 | $1,215.68 |
DisclosureSEC source: 0001104659-20-000976 · a4.xml · nonDerivative · entry 4 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,321 F1 · shares: In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the shares listed, 56,005 shares are restricted stock. Read SEC document |
| December 26, 2019 Filed Jan 3, 2020 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 893 | $10.75 | $9,599.75 |
DisclosureSEC source: 0001104659-20-000976 · a4.xml · nonDerivative · entry 3 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,437 F1 · shares: In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the shares listed, 56,005 shares are restricted stock. Read SEC document |
| December 24, 2019 Filed Jan 3, 2020 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 1,412 | $10.97 | $15,489.64 |
DisclosureSEC source: 0001104659-20-000976 · a4.xml · nonDerivative · entry 2 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,330 F1 · shares: In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the shares listed, 56,005 shares are restricted stock. Read SEC document |
| December 23, 2019 Filed Jan 3, 2020 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 249 | $10.58 | $2,634.42 |
DisclosureSEC source: 0001104659-20-000976 · a4.xml · nonDerivative · entry 1 Francomano Robert · CIK 0001797467 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,742 F1 · shares: In connection with the vesting of 5,327 shares on December 21, 2019, a total of 2,670 shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 249 shares were sold on December 23, 2019; 1,412 shares were sold on December 24, 2019; 893 shares were sold on December 26, 2019; and 116 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the shares listed, 56,005 shares are restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.